Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Cutaneous B cell pseudolymphomas

Rein Willemze, MD
Section Editor
John A Zic, MD
Deputy Editor
Rosamaria Corona, MD, DSc


The term cutaneous pseudolymphoma refers to a heterogeneous group of benign skin disorders that simulate cutaneous lymphomas histologically and sometimes clinically. Cutaneous pseudolymphomas can be separated into two major subtypes, pseudolymphomas mimicking a cutaneous B cell lymphoma (B cell pseudolymphomas) and pseudolymphomas mimicking a cutaneous T cell lymphoma (T cell pseudolymphomas) (table 1) [1-3].

Cutaneous B cell pseudolymphomas (previously called lymphadenosis benigna cutis, lymphocytoma cutis, pseudolymphoma of Spiegler-Fendt, or cutaneous lymphoid hyperplasia) represent a reactive B-cell proliferation response to a variety of antigenic stimuli, including arthropod bites, gold pierced earrings, tattoo dyes, and drugs. They usually present as erythematous nodules or plaques that simulate indolent primary cutaneous B cell lymphomas, in particular primary cutaneous marginal zone lymphoma (PCMZL) or primary cutaneous follicle center lymphoma (PCFCL).

This topic will discuss the pathogenesis, clinical presentation, and differential diagnosis of B cell pseudolymphomas. Primary cutaneous B cell lymphomas, cutaneous T cell pseudolymphomas, and lymphomatoid papulosis are discussed separately.

(See "Primary cutaneous marginal zone lymphoma".)

(See "Primary cutaneous follicle center lymphoma".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Oct 2017. | This topic last updated: Jun 16, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Rijlaarsdam JU, Willemze R. Cutaneous pseudolymphomas: classification and differential diagnosis. Semin Dermatol 1994; 13:187.
  2. Ploysangam T, Breneman DL, Mutasim DF. Cutaneous pseudolymphomas. J Am Acad Dermatol 1998; 38:877.
  3. Mitteldorf C, Kempf W. Cutaneous Pseudolymphoma. Surg Pathol Clin 2017; 10:455.
  4. Glatz M, Resinger A, Semmelweis K, et al. Clinical spectrum of skin manifestations of Lyme borreliosis in 204 children in Austria. Acta Derm Venereol 2015; 95:565.
  5. Colli C, Leinweber B, Müllegger R, et al. Borrelia burgdorferi-associated lymphocytoma cutis: clinicopathologic, immunophenotypic, and molecular study of 106 cases. J Cutan Pathol 2004; 31:232.
  6. Bernstein H, Shupack J, Ackerman B. Cutaneous pseudolymphoma resulting from antigen injections. Arch Dermatol 1974; 110:756.
  7. Iwatsuki K, Yamada M, Takigawa M, et al. Benign lymphoplasia of the earlobes induced by gold earrings: immunohistologic study on the cellular infiltrates. J Am Acad Dermatol 1987; 16:83.
  8. Rijlaarsdam JU, Bruynzeel DP, Vos W, et al. Immunohistochemical studies of lymphadenosis benigna cutis occurring in a tattoo. Am J Dermatopathol 1988; 10:518.
  9. Cerroni L, Borroni RG, Massone C, et al. Cutaneous B-cell pseudolymphoma at the site of vaccination. Am J Dermatopathol 2007; 29:538.
  10. Paley K, Geskin LJ, Zirwas MJ. Cutaneous B-cell pseudolymphoma due to paraphenylenediamine. Am J Dermatopathol 2006; 28:438.
  11. Maubec E, Pinquier L, Viguier M, et al. Vaccination-induced cutaneous pseudolymphoma. J Am Acad Dermatol 2005; 52:623.
  12. Takahashi T, Hata M, Iwata H, Seishima M. Cutaneous B-cell Pseudolymphoma in a Psoriatic Patient Treated with Cyclosporine. Acta Derm Venereol 2016; 96:824.
  13. Riyaz N, Sasidharanpillai S, Aravindan KP, et al. Phenytoin Induced Cutaneous B Cell Pseudolymphoma. Indian J Dermatol 2015; 60:522.
  14. Li C, Inagaki H, Kuo TT, et al. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 asian cases. Am J Surg Pathol 2003; 27:1061.
  15. Wood GS, Kamath NV, Guitart J, et al. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States. J Cutan Pathol 2001; 28:502.
  16. Maraspin V, Nahtigal Klevišar M, Ružić-Sabljić E, et al. Borrelial Lymphocytoma in Adult Patients. Clin Infect Dis 2016; 63:914.
  17. Moreno A, Curcó N, Serrano T, et al. Disseminated, miliarial type lymphocytoma cutis. A report of two cases. Acta Derm Venereol 1991; 71:334.
  18. Arnež M, Ružić-Sabljić E. Borrelial Lymphocytoma in Children. Pediatr Infect Dis J 2015; 34:1319.
  19. Cerroni L, Signoretti S, Höfler G, et al. Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. Am J Surg Pathol 1997; 21:1307.
  20. Arai E, Shimizu M, Hirose T. A review of 55 cases of cutaneous lymphoid hyperplasia: reassessment of the histopathologic findings leading to reclassification of 4 lesions as cutaneous marginal zone lymphoma and 19 as pseudolymphomatous folliculitis. Hum Pathol 2005; 36:505.
  21. Rijlaarsdam JU, Meijer CJ, Willemze R. Differentiation between lymphadenosis benigna cutis and primary cutaneous follicular center cell lymphomas. A comparative clinicopathologic study of 57 patients. Cancer 1990; 65:2301.
  22. Leinweber B, Colli C, Chott A, et al. Differential diagnosis of cutaneous infiltrates of B lymphocytes with follicular growth pattern. Am J Dermatopathol 2004; 26:4.
  23. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768.
  24. Rijlaarsdam U, Bakels V, van Oostveen JW, et al. Demonstration of clonal immunoglobulin gene rearrangements in cutaneous B-cell lymphomas and pseudo-B-cell lymphomas: differential diagnostic and pathogenetic aspects. J Invest Dermatol 1992; 99:749.
  25. Gilliam AC, Wood GS. Cutaneous lymphoid hyperplasias. Semin Cutan Med Surg 2000; 19:133.
  26. Nihal M, Mikkola D, Horvath N, et al. Cutaneous lymphoid hyperplasia: a lymphoproliferative continuum with lymphomatous potential. Hum Pathol 2003; 34:617.
  27. Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol 2007; 25:1581.
  28. Rijlaarsdam JU, van der Putte SC, Berti E, et al. Cutaneous immunocytomas: a clinicopathologic study of 26 cases. Histopathology 1993; 23:117.
  29. Swerdlow SH, Quintanilla-Martinez L, Willemze R, Kinney MC. Cutaneous B-cell lymphoproliferative disorders: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol 2013; 139:515.
  30. Kodama K, Massone C, Chott A, et al. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood 2005; 106:2491.
  31. de Leval L, Harris NL, Longtine J, et al. Cutaneous b-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and classification. Am J Surg Pathol 2001; 25:732.
  32. Hoefnagel JJ, Vermeer MH, Jansen PM, et al. Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. Br J Dermatol 2003; 149:1183.
  33. de Leval L, Braaten KM, Ancukiewicz M, et al. Diffuse large B-cell lymphoma of bone: an analysis of differentiation-associated antigens with clinical correlation. Am J Surg Pathol 2003; 27:1269.
  34. Taylor RB, Fortney JA, Pollack RB, et al. Radiation therapy for B-cell cutaneous lymphoid hyperplasia. Jpn J Radiol 2010; 28:385.
  35. Olson LE, Wilson JF, Cox JD. Cutaneous lymphoid hyperplasia: results of radiation therapy. Radiology 1985; 155:507.
  36. Benchikhi H, Bodemer C, Fraitag S, et al. Treatment of cutaneous lymphoid hyperplasia with thalidomide: report of two cases. J Am Acad Dermatol 1999; 40:1005.
  37. Pham-Ledard A, Vergier B, Doutre MS, Beylot-Barry M. Disseminated cutaneous lymphoid hyperplasia of 12 years' duration triggered by vaccination. Dermatology 2010; 220:176.
  38. Martin SJ, Duvic M. Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab. Clin Lymphoma Myeloma Leuk 2011; 11:286.